Clinical trial NCT06990542: Image-guided, Tumor-focused Radiotherapy Treatment in Intermediate and High-risk Prostate Cancer
Official title: RAdiation Dose TAiloRing Guided by Enhanced Targeting
Study type: INTERVENTIONAL
Overall status: NOT_YET_RECRUITING
Phase: PHASE2
Conditions: Prostate Cancer
Lead sponsor: University of California, San Diego
Sponsor class: OTHER
First posted: 2025-05-25
Enrollment: 150
Sex: MALE
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: This is a phase II non-blinded randomized controlled trial of image-guided, tumor-focused radiotherapy in patients with intermediate- or high-risk prostate cancer planning to undergo definitive radiotherapy with or without systemic therapy. The image-guided, tumor-focused radiotherapy will be compared to standard, whole-prostate treatment. The investigators hypothesize that tumor-focused radiotherapy reduces the radiation dose to organs close to the prostate, possibly leading to decreased acute toxicity to the genitourinary and gastrointestinal organs. The investigators will measure acute and late genitourinary and gastrointestinal toxicity due to radiation and regardless of cause. The investigators will also measure overall survival, metastasis-free survival, and quality of life, as well as biomarkers that may help predict, in the future, who may have a worse toxicity following radiation therapy.

Detailed description: Definitive radiation therapy for prostate cancer with dose intensification and/or focal boosting has excellent oncologic outcomes. However, many patients experience long-term toxicity in particular to the genitourinary and gastrointestinal organs, impacting their quality of life. Given the excellent survivorship after definitive prostate cancer treatment, there is interest in identifying strategies that can improve the therapeutic ratio and minimize toxicity while maintaining excellent oncologic outcomes. Intraprostatic recurrence after definitive radiation therapy occurs at the site of the primary tumor and the dose to the site of the primary tumor is an important predictor of future treatment failure. This leads to the hypothesis that, if accurate discrimination between tumor(s) and benign prostate tissue can be achieved, radiation oncologists can devise tumor-focused radiation therapy plans that deliver ablative dose radiation therapy to the tumor(s) and de-escalated dose to the remainder of the electively irradiated prostate. This strategy is now possible thanks to advanced imaging technologies that can accurately identify the primary clinically significant tumor(s) to be targeted. De-escalated dose to the remainder of the prostate may lead to low dose also to neighboring organs, such as rectum and bladder, potentially leading to lower rates of acute and late toxicity and minimizing the impact of prostate cancer treatment on quality of life. A randomized trial is required to compare the efficacy and toxicity of tumor-focused radiation therapy to that of standard radiation therapy for definitive treatment of localized prostate cancer.

Eligibility criteria: Inclusion Criteria:

* Provision of signed and dated informed consent form
* Stated willingness to comply with all study procedures and availability for the duration of the study
* At least 18 years old
* Histologic confirmation of prostate adenocarcinoma with plan for curative-intent radiation therapy
* Lesion visible on prostate Magnetic Resonance Imaging and/or Prostate-Specific Membrane Antigen Positron Emission Tomography-Computed Tomography (according to the treating physician) with concordant pathology from biopsy needle locations.
* For participants able to cause a pregnancy: use of condoms or other methods to ensure effective contraception with partner during the radiation therapy treatment and for at least 6 months afterward.

Exclusion Criteria:

* Bilateral hip implants
* Prior prostatectomy
* Prior prostate cancer treatment (for example, focal therapy). Note that participants who started hormone therapy within the 90 days prior to randomization are eligible, as long as study-compatible imaging was performed within the 4 months prior to starting the hormone therapy.
* Prior radiation therapy to an area requiring treatment in the present study

Primary outcomes:
measure: Acute toxicity
timeFrame: 3 months
Secondary outcomes:
Other outcomes:
Locations:
Study officials:
affiliation: University of California, San Diego
name: Tyler Seibert, MD, PhD
role: PRINCIPAL_INVESTIGATOR
References: